Biotechnology News and Research

RSS

biospace med raises $18M to accelerate market penetration of EOS imaging system in North America and Europe

biospace med announced today that it has raised $18 million to accelerate market expansion in North America and Europe of the company's FDA-cleared EOS ultra-low-dose 2D/3D imaging system.

15 Apr 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.

15 Apr 2010

PSI acquires PEG-based technology

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology covers a series of PEG-grafted cationic polymers that have a wide variety of applications in the pharmaceutical arena.

15 Apr 2010

Articulinx closes $10M Series B financing round

Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).

15 Apr 2010

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Building upon its powerful BD™ LSR cell analyzer platform, BD Biosciences launched today a new off-the-shelf BD LSRFortessa™ System, which uses up to four lasers -- blue, red, violet and UV -- that enable the detection of up to 18 colors simultaneously.

15 Apr 2010

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) to the U.S. Food and Drug Administration (FDA) for approval as a treatment for opioid dependence. The company requested a priority review for its sNDA and if granted by the FDA, it would mean a six month review timeline.

13 Apr 2010

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.

13 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Sigma Life Science announces latest version of 'Your Favorite Gene Powered By Ingenuity' research portal

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced a significant expansion to its web-based biological research portal for exploring dynamic gene-based content, Your Favorite Gene Powered By Ingenuity (http://www.wherebiobegins.com/yfg).

13 Apr 2010

Perceptive Informatics expands medical imaging capabilities with enhanced reporting solution

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with an enhanced reporting solution.

From Parexel 13 Apr 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.

13 Apr 2010

Silence Therapeutics reorganizes resources following Intradigm merger

Silence Therapeutics plc announces that the Company is executing a strategic plan designed to optimally organize its resources following its recent merger with Intradigm Corporation. Moving forward, all research activities related to Silence's novel RNA interference (RNAi) therapeutic platforms, including technologies that have emerged from both Silence and Intradigm, will take place at the Company's Berlin location.

13 Apr 2010

NeoStem opens new adult stem cell collection center in Austin, TX

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010.

13 Apr 2010

Copaxone achieves one million patient years of experience in treatment of RRMS

Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

13 Apr 2010

ABRAXANE accepted for restricted use within Scotland NHS

Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.

13 Apr 2010

Genzyme, Arecor establish strategic partnership for developing advanced protein therapeutic formulations

Genzyme Corporation and Arecor Limited today signed an agreement providing for extensive collaboration on developing advanced formulations for protein therapeutics. The agreement provides for a close working relationship between Genzyme and Arecor in developing stable, high strength formulations of labile biomolecules. This agreement is the result of a two year working relationship where Arecor has demonstrated their technologies offer an improvement over conventional approaches in protein formulation.

13 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Biotechnology News and Research

biospace med raises $18M to accelerate market penetration of EOS imaging system in North America and Europe

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

PSI acquires PEG-based technology

Articulinx closes $10M Series B financing round

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Alkermes submits VIVITROL sNDA for opioid dependence

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Sigma Life Science announces latest version of 'Your Favorite Gene Powered By Ingenuity' research portal

Perceptive Informatics expands medical imaging capabilities with enhanced reporting solution

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

XOMA expands anti-inflammatory antibody intellectual property portfolio

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

Silence Therapeutics reorganizes resources following Intradigm merger

NeoStem opens new adult stem cell collection center in Austin, TX

Copaxone achieves one million patient years of experience in treatment of RRMS

ABRAXANE accepted for restricted use within Scotland NHS

Genzyme, Arecor establish strategic partnership for developing advanced protein therapeutic formulations

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News